Close Menu

NEW YORK (GenomeWeb) – Natera has filed a suit against Bio-Reference Laboratories claiming that the firm breached a contract with Natera when it launched and promoted a noninvasive prenatal test based on Illumina's technology, according to a research note issued this morning by investment bank Piper Jaffray.

Bio-Reference has been offering Natera's Panorama noninvasive prenatal screening test since 2013, but last month it launched its own NIPS, ClariTest, which is based on technology it licensed from Illumina.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jun
13

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type. 

Jun
17

This webinar will provide an overview of polygenic risk scores, which aggregate dozens of genetic variants that have been linked to disease risk in genome-wide association studies (GWAS) into a single score.

Jun
18
Sponsored by
ArcherDX

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect.